Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Recurrent/Refractory IDH-Mutant Gliomas
NCT06776250Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Aug 2025
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of tarlatamab in glioma, sponsored by University Health Network. Started Aug 2025; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06776250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06776250.